Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CD44 |
| Gene Name: | CD44 |
| Protein Full Name: | CD44 antigen |
| Alias: | CD44 antigen precursor; CD44 molecule; CD44R; CDw44; Chondroitin sulfate proteoglycan 8; CSPG8; ECMR-III; Epican; Extracellular matrix receptor-III; GP90 lymphocyte homing/adhesion receptor; HCELL; Hematopoietic cell E- and L-selectin ligand; Heparan sulfate proteoglycan; Hermes antigen; HUTCH-I; Hyaluronate receptor; IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1; PGP-1; Phagocytic glycoprotein I |
| Mass (Da): | 81554 |
| Number AA: | 742 |
| UniProt ID: | P16070 |
| Locus ID: | 960 |
| COSMIC ID: | CD44 |
| Gene location on chromosome: | 11p13 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.48 |
| Gene undergoes hypermethylation: | Promotor region hypermethylated in prostate cancer |
| Normal role description: | CD44 is a receptor, which interacts with various ligands and is crucial for cell-matrix and cell-cell interactions. One principal ligand is hyaluronic acid. CD44 is involved in uptake and degradation of hyaluronic acid. It is suggested to be a candidate for prognostic or diagnostic marker and is overexpressed in various cancer types. May be a growth advantage and promote metastasis in some tumors. However some cancers/ cancer stages are associated with significant downregulation of some splicing variants of CD44 expression. |